Financial Performance - Total assets increased to ¥2,739,214,008.95, representing a growth of 111.20% compared to the end of the previous year[7]. - Net assets attributable to shareholders reached ¥2,348,192,478.21, up 117.08% year-over-year[7]. - Revenue for the reporting period was ¥411,280,826.79, reflecting a 105.01% increase compared to the same period last year[7]. - Net profit attributable to shareholders was ¥144,308,175.17, a significant rise of 219.81% year-over-year[7]. - Basic earnings per share increased to ¥0.68, representing a growth of 223.81% compared to the same period last year[7]. - The weighted average return on equity was 9.33%, an increase from 4.86% in the previous year[7]. - Total operating revenue for Q3 2020 reached ¥411,280,826.79, a significant increase from ¥200,618,974.94 in the same period last year, representing a growth of 105.5%[44]. - Operating profit for the period was ¥179,047,393.85, compared to ¥46,910,695.67 in the previous year, indicating an increase of 281.5%[46]. - Net profit for Q3 2020 was ¥151,307,745.14, up from ¥40,321,221.55 in Q3 2019, reflecting a growth of 274.5%[46]. - Total comprehensive income for the period was ¥298,256,478.64, compared to ¥96,725,015.13 in the previous year, indicating a substantial increase[54]. Cash Flow - Net cash flow from operating activities was ¥79,183,177.38, up 163.98% year-over-year[7]. - Cash received from sales and services increased by 49.57% to ¥720,216,162.35 compared to ¥481,515,447.15 in the same period last year, primarily due to expanded sales scale and increased cash recovery[22]. - Cash received from other operating activities surged by 1,139.95% to ¥28,059,860.37, up from ¥2,262,978.44, mainly due to the recovery of withheld taxes[22]. - The net cash flow from operating activities for Q3 2020 was CNY 121,454,522.72, a significant increase from CNY 50,026,117.52 in Q3 2019, representing a growth of approximately 142.6%[61]. - Total cash inflow from operating activities reached CNY 748,276,022.72, compared to CNY 483,781,895.18 in the same period last year, indicating a year-over-year increase of about 54.9%[61]. - Cash outflow for purchasing goods and services was CNY 212,820,491.05, compared to CNY 77,779,360.96 in Q3 2019, indicating an increase of about 172.5%[61]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,846[11]. - The largest shareholder, Hong Kong Science and Technology Venture Co., Ltd., holds 29.15% of the shares[11]. - The company completed the issuance of 22,945,804 shares to specific investors, with a lock-up period of 6 to 18 months for different shareholders[16]. - The company successfully issued 22,945,804 shares at a price of ¥45.76 per share, raising a total of ¥1,049,999,991.04, with a net amount of ¥1,027,419,602.53 after expenses[24]. Assets and Liabilities - Current assets totaled CNY 2,039,001,503.79, up from CNY 664,630,142.30, indicating a growth of about 207%[36]. - Total liabilities amounted to CNY 252,156,423.26, up from CNY 112,328,167.48, representing an increase of approximately 124%[38]. - Shareholders' equity reached CNY 2,487,057,585.69, compared to CNY 1,184,640,009.97, indicating a growth of about 110%[39]. - The company reported inventory of CNY 43,413,968.27, indicating a significant asset base for operations[68]. Investment and Development - The company has invested CNY 16,849,970.13 in development expenditures, up from CNY 9,393,901.83, reflecting an increase of about 79%[37]. - Research and development expenses for the quarter were ¥17,550,599.39, compared to ¥15,994,988.43 in the previous year, an increase of 9.7%[45]. - The company plans to continue expanding its market presence and investing in new product development[56]. Compliance and Governance - The company has no violations regarding external guarantees during the reporting period[28]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[29]. - The company executed the new revenue recognition standards starting January 1, 2020, which may affect future financial reporting[71]. - The Q3 2020 report was not audited, indicating preliminary financial data[77].

广东凯普生物科技股份有限公司 2020 年半年度报告全文 广东凯普生物科技股份有限公司 2020 年半年度报告 公司负责人黄伟雄、主管会计工作负责人李庆辉及会计机构负责人(会计主 管人员)罗翠红声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测 与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意公司面临的风险 因素，详见本报告第四节"经营情况讨论与分析"之"九、公司面临的风险和应对 措施"部分。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 (公告编号：2020-104) 广东凯普生物科技股份有限公司 2020 年半年度报告全文 2020 年 08 月 第一节 重要提示、目录和释义 1 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 2 | 目录 | | --- | | 2020 | 年半年度报 ...

Financial Performance - Total operating revenue for the first quarter was ¥149,713,684.31, representing a 9.39% increase compared to ¥136,858,532.28 in the same period last year[7] - Net profit attributable to shareholders was ¥19,739,403.97, up 15.57% from ¥17,079,387.21 year-on-year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,602,137.14, reflecting a 17.60% increase from ¥14,967,728.19 in the previous year[7] - Basic earnings per share increased to ¥0.09, a rise of 12.50% from ¥0.08 in the same period last year[7] - The company achieved total revenue of 149.71 million yuan in Q1 2020, a year-on-year increase of 9.39%[18] - Net profit attributable to shareholders was 19.74 million yuan, up 15.57% compared to the same period last year[18] - Net profit for Q1 2020 was CNY 24,759,408.12, up from CNY 15,836,782.78 in the same period last year, representing a growth of approximately 56.5%[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,381,029,025.43, up 6.48% from ¥1,296,968,177.45 at the end of the previous year[7] - The company's total assets amounted to CNY 1,381,029,025.43, an increase from CNY 1,296,968,177.45 at the end of 2019, reflecting a growth of approximately 6.5%[43] - The company's total liabilities increased to CNY 165,038,570.85 from CNY 112,328,167.48, reflecting a growth of approximately 46.9%[45] - The company's equity decreased to CNY 1,215,990,454.58 from CNY 1,184,639,009.97, indicating a decline of about 2.6%[45] Cash Flow - The net cash flow from operating activities was negative at -¥24,458,088.61, a significant decrease of 2,182.35% compared to -¥1,071,618.69 in the same period last year[7] - Cash flow from operating activities showed a net outflow of 24.46 million yuan, a significant decline compared to the previous year[17] - The cash flow from operating activities shows a net outflow of CNY -24,458,088.61, compared to CNY -1,071,618.69 in the previous period, indicating worsening cash flow conditions[61] - Operating cash inflow for the current period was CNY 33,732,573.40, an increase of 55.8% compared to CNY 21,655,940.16 in the previous period[64] - Net cash flow from operating activities was CNY 6,065,799.75, a significant recovery from a net outflow of CNY -9,490,551.94 in the previous period[64] Research and Development - The company’s R&D expenses reached 12.52 million yuan, a 40.15% increase year-on-year, driven by the development of various COVID-19 testing reagents[16] - The company invested CNY 13.0975 million in R&D, representing a year-on-year increase of 11.29%[23] - The company has developed three new COVID-19 nucleic acid testing products, contributing to pandemic prevention efforts[23] - Research and development expenses increased to CNY 12,523,044.28 from CNY 8,935,689.08, showing a rise of about 40.0%[52] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,519[10] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., held 33.24% of the shares, totaling 70,615,200 shares[10] - The company has reduced its total share capital from 217,381,347 shares to 212,454,284 shares by canceling 4,927,063 repurchased shares[32] - The company proposed a cash dividend of CNY 2.00 per 10 shares, pending approval from the annual general meeting[33] Market and Competition - The company is facing risks from intensified market competition and is committed to improving its R&D capabilities and product offerings[26] - The company aims to strengthen its competitive advantage through the "Nucleic Acid 99" strategy, focusing on new product development and marketing network enhancement[26] Regulatory and Management - The company has established a risk management mechanism to address potential regulatory and operational risks[25] - The company is implementing a scientific decision-making mechanism to enhance management capabilities as it expands its business scale[28] - The company is implementing new revenue and leasing standards starting in 2020, which may affect future financial reporting[72]

Financial Performance - The company reported a total revenue of 300 million RMB for the year 2019, representing a year-on-year increase of 15% compared to 2018[13]. - The net profit attributable to shareholders was 50 million RMB, which is a 10% increase from the previous year[13]. - The company's operating revenue for 2019 was ¥729,392,802.06, representing a 25.68% increase compared to ¥580,352,056.71 in 2018[20]. - The net profit attributable to shareholders for 2019 was ¥147,290,874.46, a 29.11% increase from ¥114,079,529.18 in 2018[20]. - The net cash flow from operating activities for 2019 was ¥112,831,785.25, up 40.36% from ¥80,390,222.68 in 2018[20]. - The total assets at the end of 2019 were ¥1,296,968,177.45, a 9.15% increase from ¥1,188,258,637.41 at the end of 2018[21]. - The net assets attributable to shareholders at the end of 2019 were ¥1,081,718,095.26, an 11.81% increase from ¥967,448,858.22 at the end of 2018[21]. - The basic earnings per share for 2019 were ¥0.70, a 32.08% increase from ¥0.53 in 2018[20]. - The weighted average return on equity for 2019 was 14.49%, up from 11.66% in 2018[20]. - The company achieved total revenue of ¥729.39 million in 2019, representing a year-on-year increase of 25.68% compared to ¥580.35 million in 2018[103]. - Net profit attributable to shareholders reached 147.29 million yuan, up 29.11% year-on-year, while the net profit after deducting non-recurring gains and losses was 135.34 million yuan, reflecting a growth of 36.03%[78]. Dividend Policy - The company plans to distribute a cash dividend of 2 RMB per 10 shares, based on a total share capital of 212,454,284 shares as of December 31, 2019[5]. - The total distributable profit as of the reporting period was RMB 229.19 million, after deducting the legal surplus reserve of RMB 1.45 million[180]. - The company proposed a cash dividend of RMB 2.00 per 10 shares, amounting to a total cash dividend of RMB 42.49 million, which represents 100% of the profit distribution[180][182]. - The cash dividend for 2019 accounted for 28.85% of the consolidated net profit attributable to shareholders[182]. - The company has maintained a consistent cash dividend policy over the past three years, reflecting stable operational performance and positive growth outlook[180][182]. - The company plans to maintain a stable profit distribution policy, ensuring cash dividends account for at least 10% of the distributable profit each year[186]. Market Expansion and Strategy - The company aims to expand its market presence in Southeast Asia, targeting a 20% growth in international sales by 2021[13]. - Future guidance indicates a projected revenue growth of 18% for 2020, driven by new product launches and market expansion[13]. - The company is focused on expanding its market reach and enhancing its product offerings through continuous research and development[36]. - The company is focused on developing new technologies and products to enhance its competitive position in the molecular diagnostics and independent laboratory sectors[55]. - The company aims to strengthen its market presence through strategic partnerships and potential acquisitions in the healthcare sector[120]. - The company is committed to enhancing shareholder value, with plans for a dividend payout ratio of 30% of net profits in the upcoming fiscal year[192]. Research and Development - The company has invested 30 million RMB in R&D for new technologies in the field of in vitro diagnostics[13]. - Research and development investment reached CNY 61.86 million, a 24.84% increase year-on-year, accounting for 8.48% of operating revenue[70]. - The company has obtained a total of 31 patents, including 19 invention patents, and has registered 27 medical device certificates, with 21 being Class III[70]. - The company is actively involved in drafting national standards for gene testing kits and has participated in significant research projects related to genetic disease testing[69]. - The company plans to increase R&D investment to accelerate new product development and enhance market share in the rapidly growing nucleic acid molecular diagnostics sector[119]. Product Development and Innovation - New product development includes a focus on molecular diagnostics, with an expected launch of three new products in 2020[13]. - The company has developed nucleic acid detection reagents and instruments covering infectious and genetic diseases, including HPV detection products and thalassemia gene testing products, with a total of 27 medical device registration certificates obtained[32]. - The company has developed automated nucleic acid extraction instruments and rapid hybridization instruments for medical use, enhancing the efficiency of nucleic acid testing[35]. - The company has a comprehensive product line that includes nucleic acid extraction kits and disposable cervical cell collectors, supporting the collection and testing of samples[35]. - The company has developed a comprehensive product matrix for STD nucleic acid testing, including single, dual, triple, and ten-plex tests to meet diverse clinical diagnostic needs[63]. Regulatory Compliance and Risk Management - The company has identified key risks for future operations, including regulatory changes and market competition, which may impact growth[5]. - The company is committed to maintaining compliance with industry regulations to mitigate risks associated with policy changes and regulatory scrutiny[168]. - The company has received regulatory approvals for various medical devices, ensuring compliance and enhancing market credibility[122]. Market Trends and Opportunities - The in vitro diagnostic market in China is projected to grow at an annual rate of over 15% in the next decade[51]. - The molecular diagnostics market in China is rapidly growing, with a compound annual growth rate (CAGR) of 35% from 2010 to 2018, increasing from approximately RMB 1.2 billion to RMB 14 billion[56]. - The penetration rate of third-party medical laboratory services in China is only about 5%, compared to over 35% in developed countries, indicating significant growth potential[56]. - The company anticipates that the molecular diagnostics industry will benefit from increased healthcare investment and the introduction of advanced diagnostic technologies[55]. Corporate Governance and Shareholder Relations - The company emphasizes that non-recurring gains and losses cannot be used for cash dividends[186]. - The company has committed to avoiding competition with its actual controllers and related entities to ensure stable development and protect minority shareholders' interests[187]. - The company will require new directors and senior management to sign commitment letters to ensure compliance with previous commitments made during the IPO[188].

广东凯普生物科技股份有限公司 2019 年第三季度报告全文 广东凯普生物科技股份有限公司 2019 年第三季度报告 （公告编号：2019-076） 2019 年 10 月 1 广东凯普生物科技股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟雄、主管会计工作负责人李庆辉及会计机构负责人(会计主 管人员)罗翠红声明：保证季度报告中财务报表的真实、准确、完整。 2 广东凯普生物科技股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,239,664,012.23 | | 1,188,258,637.41 | 4.33% | | 归属于上 ...

Financial Performance - The company reported a total revenue of RMB 217.42 million for the first half of 2019, representing a year-on-year increase of 15% compared to RMB 189.06 million in the same period of 2018[11]. - The net profit attributable to shareholders for the first half of 2019 was RMB 45.36 million, an increase of 20% from RMB 37.80 million in the first half of 2018[11]. - Total revenue for the reporting period reached ¥317,062,992.63, representing a 27.02% increase compared to the same period last year[18]. - Net profit attributable to shareholders was ¥59,873,427.44, up 29.34% year-over-year[18]. - The company reported a revenue of 1.20 billion, representing a 21.2% increase compared to the previous period[126]. - The company reported a revenue of 500 million in the first half of 2019, reflecting a growth of 4.5% compared to the same period last year[138]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2019, representing a year-over-year growth of 15%[165]. Market Expansion and Strategy - The company plans to focus on expanding its market presence in the field of in vitro diagnostics and molecular diagnostics, aiming for a 25% growth in market share by the end of 2020[11]. - The company is exploring potential mergers and acquisitions to enhance its product offerings and market reach, with a target completion date by the end of 2020[11]. - The company is actively expanding into the health management sector, leveraging its experience in maternal and child health services[25]. - The company aims to expand its market presence by launching new products in the second half of 2019, targeting a 15% increase in market share[129]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2020[127]. - The company is exploring market expansion opportunities in new regions to increase its market share[126]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2021[132]. Research and Development - The company has invested RMB 10 million in research and development for new diagnostic products, with plans to launch at least three new products by the end of 2019[11]. - The company has developed a series of molecular diagnostic products, including HPV testing series and thalassemia gene testing products, with 18 products approved as Class III medical devices[26]. - The company has a strong R&D team with 26 PhDs and 122 Masters, focusing on molecular diagnostic reagents and instruments[61]. - The company aims to increase R&D investment and accelerate new product development to enhance market share in the rapidly growing nucleic acid molecular diagnostics sector[63]. - Research and development expenses rose by 24.82% to RMB 25,519,420.08, driven by the implementation of the "Nucleic Acid 99" strategy[96]. - The company is investing in R&D with a budget increase of 30% for new technologies[134]. Product Development and Innovation - The company has developed multiple technical platforms for medical testing, including Fluorescent PCR, NGS (Next-Generation Sequencing), and Tandem Mass Spectrometry, adhering to ISO15189 standards[30]. - The company is actively involved in research and development of new HPV testing technologies, including high-risk HPV E6/E7 mRNA testing kits, which are currently in clinical stages[41]. - The company has developed fully automated nucleic acid extraction instruments, which are expected to enhance efficiency in DNA/RNA extraction processes across various applications[100]. - The company is focusing on long-term product development, with several nucleic acid extraction kits and instruments designed for clinical and research use, ensuring high purity and concentration of extracted nucleic acids[100]. - The company is committed to enhancing its product line with advanced technologies, as evidenced by its various nucleic acid extraction methods[101]. Financial Health and Investments - The total assets of the company as of June 30, 2019, amounted to RMB 1.2 billion, reflecting a 10% increase from RMB 1.09 billion at the end of 2018[11]. - The company’s total liabilities as of June 30, 2019, were RMB 500 million, representing a debt-to-equity ratio of 0.42[11]. - The company reported a significant increase in cash flow from operating activities, which increased by 72.01% to ¥20,030,101.61[18]. - The company’s fixed assets increased by CNY 20.43 million compared to the beginning of the reporting period, primarily due to the purchase of properties for medical testing and the conversion of new production lines into fixed assets[57]. - The company reported a significant increase in treasury stock, which rose to CNY 96,063,857.96, a 6.08% increase from CNY 23,452,020.00, due to share repurchases[1]. Compliance and Risk Management - The company has identified key risks including market competition and regulatory changes, and has developed strategies to mitigate these risks[5]. - The company is committed to complying with relevant laws and regulations to establish effective decision-making and internal management mechanisms[152]. - The management emphasized the importance of adhering to regulatory requirements and maintaining transparency in all operations[181]. - The company has established strict production and operational management systems to mitigate regulatory risks associated with industry policies[150]. User Engagement and Market Demand - User data shows an increase in active users by 20% compared to the previous year[124]. - User data indicated a growth in active users by 20.7% month-over-month, reaching a total of 4.20 million active users[129]. - User data showed an increase in active users by 15% compared to the previous year, reaching a total of 1.2 million active users[179]. - The user data indicates a significant increase in active users, contributing to the overall revenue growth[141]. Corporate Governance and Shareholder Relations - The company will not distribute cash dividends or issue bonus shares for the half-year period[155]. - The company has committed to protecting the rights and interests of shareholders and investors through various measures[183]. - The company is committed to maintaining compliance with the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[175].

Financial Performance - Total operating revenue for Q1 2019 was CNY 136,858,532.28, an increase of 27.98% compared to CNY 106,936,394.21 in the same period last year[7] - Net profit attributable to shareholders was CNY 17,079,387.21, representing a growth of 38.84% from CNY 12,301,546.48 year-on-year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 14,967,728.19, up 25.49% from CNY 11,927,875.67 in the previous year[7] - Basic earnings per share increased to CNY 0.09, a rise of 28.57% compared to CNY 0.07 in the same period last year[7] - The company achieved total operating revenue of CNY 136.86 million in Q1 2019, a year-on-year increase of 27.98%[17] - Net profit attributable to ordinary shareholders of the parent company was CNY 17.08 million, up 38.84% compared to the same period last year[17] - The company's operating profit rose to ¥17,227,486.83 from ¥13,727,727.60, indicating a growth of around 25%[41] - The total profit for the current period was ¥16,474,459.34, up from ¥13,150,652.14, which is an increase of about 25%[41] Cash Flow and Assets - The net cash flow from operating activities improved significantly to -CNY 1,071,618.69, a decrease of 89.64% from -CNY 10,347,956.42 in the previous year[7] - Cash received from sales of goods and services was CNY 134.75 million, reflecting a 39.31% increase due to expanded sales scale[16] - Cash inflow from investment activities reached CNY 230,984,521.70, significantly higher than CNY 60,668,357.81 in the previous period, marking an increase of approximately 279.5%[49] - Cash and cash equivalents increased significantly from CNY 677,659.13 to CNY 5,329,076.98, a growth of approximately 685.5%[35] - Cash and cash equivalents at the end of the period amounted to CNY 67,393,573.76, compared to CNY 189,630,190.79 at the end of the previous period, indicating a decrease of approximately 64.5%[50] - Total current assets decreased from CNY 709,305,549.50 to CNY 701,196,276.49, a decline of approximately 1.56%[31] - Total non-current assets increased from CNY 478,953,087.91 to CNY 487,874,780.62, an increase of about 1.92%[31] - Total assets increased slightly from CNY 1,188,258,637.41 to CNY 1,189,071,057.11, reflecting a growth of approximately 0.07%[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,744[11] - The company reported cash dividends of RMB 2.50 per 10 shares and a capital reserve increase of 2 shares for every 10 shares held, increasing total share capital from 182,008,000 to 217,424,187 shares[22] - Net assets attributable to shareholders increased to CNY 983,344,947.89, reflecting a growth of 1.64% from CNY 967,448,858.22 at the end of the previous year[7] Research and Development - R&D expenses were CNY 8.94 million, reflecting a reclassification from management expenses[16] - The company plans to enhance R&D investment in molecular diagnostic reagents to strengthen its market position[17] - The company has adopted the M-IPD research and development management model to strengthen its innovation system and risk management[20] Market and Operational Insights - Revenue from HPV testing products grew by 16.64% year-on-year, while revenue from thalassemia, STD, and deafness susceptibility gene testing increased by 49.04%[17] - Medical testing service revenue surged by 97.01% compared to the previous year, indicating strong market demand[17] - The company aims to enhance its core competitiveness through the "Nucleic Acid 99" strategy, focusing on new product development and marketing network improvement[19] - The company has established a rigorous production and operational management system, along with a rapid response risk prevention mechanism to comply with regulatory requirements and industry policies[19] Risks and Challenges - The company faces risks related to the inability to achieve profitability in its medical laboratory business due to significant short-term investments[21] - The company emphasizes the importance of adjusting and optimizing its management system in response to rapid business expansion to mitigate management risks[20]

Financial Performance - The company's operating revenue for 2018 was CNY 580,352,056.71, representing a 21.14% increase compared to CNY 479,085,119.83 in 2017[15]. - The net profit attributable to shareholders for 2018 was CNY 114,079,529.18, up 22.39% from CNY 93,210,017.92 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was CNY 99,492,512.01, reflecting a 19.42% increase from CNY 83,312,524.79 in 2017[15]. - The basic earnings per share for 2018 was CNY 0.63, a 10.53% increase from CNY 0.57 in 2017[15]. - The total assets at the end of 2018 amounted to CNY 1,188,258,637.41, an increase of 11.09% from CNY 1,069,642,003.50 at the end of 2017[15]. - The net assets attributable to shareholders at the end of 2018 were CNY 967,448,858.22, a slight increase of 0.71% from CNY 960,600,384.89 in 2017[15]. - The cash flow from operating activities for 2018 was CNY 80,390,222.68, showing a 1.36% increase from CNY 79,315,207.97 in the previous year[15]. - The total profit reached 125.94 million yuan, growing by 15.02% compared to the previous year[62]. - The company achieved a total revenue of ¥580,352,056.71 in 2018, representing a year-on-year increase of 21.14% compared to ¥479,085,119.83 in 2017[78]. - The revenue from the molecular diagnostics sector was ¥534,350,782.80, accounting for 92.07% of total revenue, with a growth of 17.10% from ¥456,327,122.82 in the previous year[78]. Cash Flow and Investments - Total operating cash inflow for 2018 was CNY 557.90 million, an increase of 23.41% compared to CNY 452.07 million in 2017[103]. - Total operating cash outflow for 2018 was CNY 477.51 million, up 28.10% from CNY 372.75 million in 2017[105]. - Investment cash inflow increased by 75.94% to CNY 1,076.86 million, compared to CNY 612.07 million in the previous year[105]. - Investment cash outflow rose by 35.04% to CNY 1,277.36 million, up from CNY 945.90 million in 2017[105]. - Net cash flow from investment activities improved by 40.33%, resulting in a net outflow of CNY 200.50 million compared to CNY 333.83 million in 2017[105]. Research and Development - The company invested CNY 49.55 million in R&D during the reporting period, a 31.04% increase year-on-year, accounting for 8.54% of total revenue[52]. - The company has a strong R&D team of 263 personnel, including 11 PhDs and 60 Master's degree holders, and has been granted 21 patents, of which 17 are invention patents[52]. - The company aims to enhance its competitive position and market influence by increasing R&D investment and accelerating new product development[92]. - The company has launched multiple new products, including a PCR-based kit for β-thalassemia gene testing and a quantitative detection kit for hepatitis B virus, with registration dates in 2020[95]. - The company is focusing on long-term product development, with several instruments and kits designed for clinical auxiliary diagnosis and research purposes[96]. Market Expansion and Product Development - The company is focused on expanding its molecular diagnostic product sales and medical testing services through strategic partnerships and resource integration[29]. - The company aims to enhance its market presence through the introduction of new technologies and products in the healthcare sector[99]. - The company plans to invest no less than 50 million yuan annually in R&D over the next three years, with the goal of launching over 20 new R&D projects each year[140]. - The company aims to achieve comprehensive coverage of nucleic acid molecular diagnostic products in the domestic market within 3-5 years[140]. - The company is implementing the "Nucleic Acid 99" development strategy to expand its nucleic acid molecular diagnostic product line, focusing on genetic and infectious disease detection[139]. Regulatory Compliance and Governance - The company has committed to maintaining transparency and compliance with the regulations set by the China Securities Regulatory Commission and Shenzhen Stock Exchange[176]. - The company has established a profit distribution policy that requires adjustments based on actual conditions, which must be approved by a majority of directors and shareholders[167]. - The company will not distribute cash dividends if the asset-liability ratio exceeds 75% at year-end[166]. - The company’s profit distribution policy emphasizes reasonable returns to investors while ensuring sustainable development[165]. - The company has confirmed that all commitments made to minority shareholders have been fulfilled on time[185]. Strategic Initiatives and Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[182]. - The company has set a performance guidance of 1.8 billion RMB for the next fiscal year, indicating a strong growth trajectory[180]. - The management emphasized the importance of compliance with regulatory commitments and maintaining transparency with investors[181]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[181]. - The company aims to build a high-quality management team through the "Kep Future Leader Training Program" to support its strategic goals and improve operational efficiency[145].

Financial Performance - Operating revenue for the current period reached CNY 155,202,075.13, a year-on-year increase of 23.59%[7] - Net profit attributable to shareholders increased by 16.75% to CNY 32,225,676.90 for the current period[7] - Basic earnings per share rose by 15.84% to CNY 0.1777[7] - Total operating revenue for the period reached CNY 404,809,680.91, an increase from CNY 335,890,485.01 in the previous period, representing a growth of approximately 20.5%[47] - Net profit for the period was CNY 30,747,929.73, compared to CNY 26,839,506.27 in the same period last year, reflecting an increase of about 14.2%[40] - Earnings per share (EPS) for the period was CNY 0.1777, up from CNY 0.1534 in the previous period, indicating a growth of approximately 15.8%[41] - The company reported a total comprehensive income of CNY 32,626,124.79 for the period, compared to CNY 27,855,595.96 in the previous period, representing an increase of about 17.5%[41] - The company experienced an asset impairment loss of CNY 3,142,138.34, compared to CNY 2,018,433.30 in the previous period, indicating an increase of approximately 55.6%[47] Assets and Liabilities - Total assets increased by 9.30% to CNY 1,169,154,637.85 compared to the end of the previous year[7] - The company's total assets rose to ¥1,169,154,637.85, compared to ¥1,069,642,003.50 at the beginning of the period, reflecting a growth of 9.3%[33] - Non-current assets totaled ¥456,546,364.87, an increase from ¥372,390,577.16, indicating a growth of 22.6%[33] - The total liabilities decreased to ¥89,715,297.34 from ¥98,741,888.61, a reduction of 9.4%[33] - The equity attributable to shareholders of the parent company was ¥963,729,691.41, slightly up from ¥960,600,384.89, showing a marginal increase of 0.2%[33] Cash Flow - Cash flow from operating activities decreased by 29.03% to CNY 26,668,536.09 year-to-date[7] - The cash and cash equivalents decreased from 185.76 million yuan at the beginning of the period to 79.26 million yuan at the end of the period[30] - The net cash flow from operating activities for the current period is ¥112,232,502.52, compared to a negative cash flow of ¥19,586,279.36 in the previous period, indicating a significant improvement[57] - The total cash inflow from operating activities is ¥228,494,034.17, significantly higher than the previous period's inflow of ¥90,649,520.25[57] - The cash flow from financing activities shows a net outflow of -¥97,341,860.77, compared to a net inflow of ¥387,072,828.03 in the previous period[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,932[12] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., holds 32.33% of the shares[12] - As of the report date, the company has repurchased 3,026,763 shares, totaling 52,523,031.62 yuan, accounting for 1.66% of the total share capital[19] - The maximum and minimum repurchase prices were 18.85 yuan/share and 15.55 yuan/share, respectively[19] Research and Development - R&D expenses increased by 32.75% compared to the same period last year, mainly due to increased R&D investment[17] - Research and development expenses amounted to CNY 31,288,192.37, compared to CNY 23,569,056.74 in the previous period, showing an increase of about 32.7%[47] - Research and development expenses increased significantly to ¥12,969,925.73, representing an increase of 79.5% compared to ¥7,222,515.81 in the previous year[38] Investment Income - Revenue from investment income increased by 113.54% compared to the same period last year, mainly due to increased cash management income[17] - Investment income for the period was CNY 6,522,985.85, compared to CNY 3,054,636.21 in the previous period, reflecting an increase of approximately 113.8%[47] - The company reported an increase in investment income to CNY 53,380,852.55 from CNY 3,054,636.21 in the previous year[51] Operating Costs - Total operating costs amounted to ¥123,390,832.55, up 27.1% from ¥96,988,140.38 year-over-year[38] - Total operating costs for the period were CNY 329,251,692.88, up from CNY 265,330,883.40, which is an increase of approximately 24.1%[47] - Management expenses increased by 30.22% compared to the same period last year, primarily due to increased office rental expenses[17] Other Financial Metrics - The company received government subsidies amounting to CNY 3,694,613.59 during the reporting period[10] - Other income for the period was CNY 3,694,613.59, down from CNY 5,586,145.30 in the previous period, indicating a decrease of about 33.9%[47] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[40]

Financial Performance - The company reported a total revenue of RMB 91,017,000 for the first half of 2018, marking a significant increase compared to the same period in 2017[19]. - Total revenue for the reporting period reached ¥249,607,605.78, an increase of 18.69% compared to ¥210,310,198.55 in the same period last year[22]. - Net profit attributable to shareholders was ¥46,293,186.03, reflecting a growth of 23.20% from ¥37,576,993.09 year-on-year[22]. - Net profit after deducting non-recurring gains and losses was ¥40,521,280.43, up 16.45% from ¥34,796,853.11 in the previous year[22]. - The company achieved a revenue of 249.61 million yuan in the first half of 2018, representing an 18.69% increase compared to the same period last year[49]. - The net profit attributable to shareholders reached 46.29 million yuan, marking a 23.20% growth year-on-year[49]. - Revenue from molecular diagnostic products grew by 15.19%, while revenue from medical testing services surged by 89.81%[49]. - The gross margin for the first half of 2018 was reported at 44.58%, indicating strong operational efficiency[95]. Capital Management - The company plans not to distribute cash dividends or issue bonus shares for the current fiscal year[5]. - The company completed a capital increase by converting capital reserves into shares, issuing 10 additional shares for every 10 shares held[19]. - The registered capital of the medical testing institution increased from 16 million yuan to 50 million yuan, reflecting significant improvements in funding and management[52]. - The total amount of raised funds is RMB 372.25 million, with a net amount after deducting issuance costs of RMB 372.25 million[76]. - The total amount of raised funds invested during the reporting period is RMB 9.63 million, with a cumulative investment of RMB 224.61 million[78]. - The remaining unused raised funds amount to RMB 154.07 million, including RMB 137 million used for cash management[78]. - The company has not changed the use of raised funds, with a change ratio of 0.00%[74]. Research and Development - The company has developed proprietary nucleic acid hybridization technology, which has received two US invention patents, enhancing its competitive edge in the market[11]. - The company is committed to continuous innovation in product development and technology to enhance its market position[11]. - The company has developed a series of products covering infectious disease detection and genetic disease detection, widely used in clinical testing and large-scale population screening[30]. - The company has 40 ongoing research projects, with 10 medical devices currently in clinical trial stages[58]. - The company plans to invest in research and development for new technologies, aiming to launch at least five innovative products in the next fiscal year[61]. Market Expansion - The company is focusing on expanding its international market, targeting a 20% increase in overseas sales by 2020[61]. - The company plans to establish 25 "Kepu Medical Testing Institutions" across major provinces and cities in China to enhance its integrated service model[45]. - The company is exploring market expansion opportunities, particularly in regions with high growth potential[94]. - The company is expanding its market presence through strategic investments and partnerships in the healthcare sector[145]. Compliance and Governance - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements made in the report[4]. - The company’s board of directors and supervisory board have confirmed the accuracy and completeness of the financial report[3]. - The company has not faced any penalties or corrective actions during the reporting period[119]. - The company is committed to transparency and adherence to regulatory standards in its financial reporting[87]. Operational Challenges - The net cash flow from operating activities decreased by 34.40% to ¥11,644,540.00, down from ¥17,752,126.35 in the same period last year[22]. - Operating costs increased by 34.83% to ¥41,234,902.80, primarily due to expanded sales scale and increased revenue from medical testing services and new products[56]. - The company faces risks related to industry policies and regulations, which could impact operational activities if compliance is not maintained[105]. - Quality control risks are present due to the high requirements for transportation and storage conditions of diagnostic reagents, which could affect product quality[106]. Shareholder Information - Basic and diluted earnings per share dropped by 49.30% to ¥0.254, compared to ¥0.501 in the previous year[22]. - The total number of shares increased from 91,017,000 to 182,034,000 after a 1:1 stock dividend distribution[151]. - The largest shareholder, Hong Kong Kechuang, holds 32.33% of shares, totaling 58,846,000 shares[157]. - The total number of common shareholders at the end of the reporting period is 17,719[157]. Investment Activities - The company invested 8 million RMB to acquire a 13.79% stake in Wuhan Aimeisen Life Technology Co., Ltd.[38]. - The company has engaged in entrusted financial management, with a total of 32,200 million CNY in entrusted investments, of which 31,400 million CNY remains outstanding[85]. - The company has been actively managing idle funds, with multiple announcements regarding cash management progress[143].